<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78913">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879046</url>
  </required_header>
  <id_info>
    <org_study_id>RC12_0394</org_study_id>
    <nct_id>NCT01879046</nct_id>
  </id_info>
  <brief_title>Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells</brief_title>
  <acronym>ARTHROSTEM</acronym>
  <official_title>Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Articular cartilage can be the seat of many diseases including osteoarthritis and traumatic
      defaults. The cartilage has no intrinsic ability to repair resulting at long term in
      function loss in the joints. Currently available treatments are not satisfactory in the long
      term, the use of mesenchymal stem cells appears to be promising due to their ability to
      multipotency and immunomodulation properties. This project aims to determine the most
      appropriate source for regenerative medicine of cartilage stem cells from tissue taken
      during arthroplasty in patients with osteoarthritis. These cells will be tested for
      different chondrogenic markers. The success of this project will consider the implementation
      of a strategy for regenerative medicine in bone and joint diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Increased expression of chondrogenic markers</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increased expression of chondrogenic markers will be Evaluated by different techniques:
in vitro: Histology fit for chondrogenic markers, RT-PCR on the following markers aggrecan, type II collagen, Sox9, Comp, type IX collagen
in vivo: In a second step, differentiated MSCs are implanted in vivo after combination with a hydrogel subcutaneously in nude mice. The formation of a neo cartilage tissue will be assessed by histology for type II collagen and aggrecan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increasing secretion of anti-inflammatory molecules in vitro</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increasing secretion of anti-inflammatory molecules in vitro will be tested by several techniques:
Microfluidic cards (TLDA assays) for the analysis of the expression of genes involved in inflammation and in the secretion of anti-inflammatory molecules Inhibition of proliferation of autologous T cells activated or not Assay for anti-inflammatory and pro-inflammatory molecules Analysis of the expression of surface markers by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Surgical intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>arthroplasty</intervention_name>
    <description>Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings</description>
    <arm_group_label>Surgical intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged over 18 years

          -  Patients with knee osteoarthritis

          -  Patients requiring total knee arthroplasty

          -  Patients who signed the consent form

        Exclusion Criteria:

          -  Patients aged less than 18 years

          -  Major Patients under guardianship

          -  Pregnant woman

          -  Infectious pathology or progressive tumor

          -  Refusal to participate in the study

          -  State of immunosuppression

          -  Congenital or acquired malformation resulting in a deformation of the knee
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ronan Guillou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Vinatier</last_name>
    <email>claire.vinatier@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérôme Guicheux</last_name>
    <email>jerome.guicheux@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Vinatier</last_name>
    </contact>
    <investigator>
      <last_name>Dr Ronan Guillou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>articular cartilage</keyword>
  <keyword>tissue engineering</keyword>
  <keyword>immunomodulation</keyword>
  <keyword>osteo-arthritis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
